BC Platform announced that it has successfully closed a Series B financing round, raising USD 10 million. The round was led by Debiopharm Innovation Fund and the Finnish venture capital and private equity company Tesi, and was supported by existing investors.
BC Platforms will use the funds to launch new technologies in 2017 that better integrate complex clinical and genomic data into its platform. The company’s aim is to provide the world’s largest leading analytics platform for health care and industry by 2020, with access to over 5 million subjects’ genomic and clinical data consolidated from a global network of biobanks, with whom BC Platforms partners. The genomic data management platform enables flexible data integration and analysis.
“We are delighted to have been supported by Debiopharm Innovation Fund and Tesi in this new financing round. This funding will enable us to progress to our next stage of expansion and to launch our new knowledge based solutions for R&D customers worldwide,” said Tero Silvola, CEO of BC Platforms.
